Peptides for Endometriosis UK: GnRH, BPC-157 & Pain Research

Endometriosis is a chronic, systemic inflammatory condition in which tissue similar to the endometrium (the lining of the uterus) grows outside the uterus — most commonly on the ovaries, fallopian tubes, bladder, bowel and pelvic peritoneum. It affects an estimated 1.5 million women and people with a uterus in the UK, making it as common as diabetes.

Despite its prevalence, endometriosis carries a diagnostic delay of 7–10 years on average in the UK — a figure that has remained stubbornly high due to persistent normalisation of period pain, limited gynaecological appointment capacity, and the fact that definitive diagnosis requires laparoscopic surgery.

The UK clinical landscape: - NHS endometriosis care is provided through general gynaecology services and, for complex cases, BSGE-accredited specialist endometriosis centres - NICE guideline NG73 (updated 2024) provides the framework for UK diagnosis and management - Treatment options include analgesics (NSAIDs, opioids for severe pain), hormonal treatments (combined oral contraceptive pill, progestogens, GnRH agonists), and surgery (laparoscopic excision)

Peptides are relevant to endometriosis in two distinct ways: GnRH agonist peptides, which are established NHS treatments suppressing ovarian function to reduce lesion activity, and research peptides such as BPC-157, which are being studied for their anti-inflammatory and tissue-protective properties in contexts potentially applicable to endometriosis-associated pain.

Gonadotrophin-releasing hormone (GnRH) agonists are peptide hormones that, when given continuously rather than in pulsatile fashion, paradoxically suppress the pituitary-gonadal axis, resulting in dramatically reduced oestrogen production — a state of temporary medical menopause.

Since endometriosis is oestrogen-dependent — endometrial lesions grow and become active in response to oestrogen — reducing oestrogen to menopausal levels suppresses lesion activity and significantly reduces pain in most patients.

GnRH agonists used in UK NHS practice:

Goserelin (Zoladex): - A synthetic GnRH agonist peptide administered as a monthly or 3-monthly subcutaneous implant into the anterior abdominal wall - Licensed for endometriosis in the UK; typically prescribed for 6-month courses (maximum 6 months due to bone density effects) - Available on the NHS through gynaecology services - Add-back therapy (low-dose oestrogen/progestogen) is co-prescribed to mitigate menopausal side effects and protect bone density

Leuprorelin (Prostap, Lupron): - Another GnRH agonist peptide administered as a monthly intramuscular or subcutaneous injection - Comparable efficacy to goserelin; choice between agents often depends on local formulary preference - Available on the NHS

Side effects of GnRH agonists: - Menopausal symptoms: hot flushes, night sweats, mood changes, vaginal dryness - Bone density loss (significant after 6 months; add-back therapy mitigates this) - Headaches, reduced libido

These medications are well-characterised peptide drugs with decades of NHS use — a fundamentally different evidence category from research peptides.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a human gastric juice protein. It has attracted significant research interest for its anti-inflammatory, tissue-protective, and angiogenesis-modulating effects in animal studies.

Proposed mechanisms potentially relevant to endometriosis: - Anti-inflammatory effects: BPC-157 has demonstrated potent inhibition of inflammatory cytokines (TNF-α, IL-6, IL-1β) in multiple rodent models — these same cytokines are elevated in peritoneal fluid of women with endometriosis and are thought to contribute to pain and lesion progression - Angiogenesis modulation: Endometriosis lesions require neovascularisation (new blood vessel formation) to grow; BPC-157 has demonstrated complex effects on angiogenesis that may theoretically modulate lesion viability - Nerve protective effects: Recent preclinical work on BPC-157 includes evidence of reduced neurogenic inflammation and peripheral nerve sensitisation — mechanisms directly relevant to the central sensitisation that underlies chronic pelvic pain in endometriosis - Tissue repair: BPC-157 consistently accelerates healing of damaged tissue in animal models; the relevance to endometriosis-associated tissue damage is theoretical but plausible

Critical limitations: - No human clinical trials for BPC-157 in endometriosis have been conducted - All evidence is from animal models; translation to human disease is unestablished - BPC-157 is not licensed by the MHRA and is a research compound only in the UK - Quality and purity of research-grade BPC-157 is unregulated

Pain is the predominant symptom driving quality-of-life impairment in endometriosis. Understanding the mechanisms of endometriosis-associated pain illuminates why both GnRH agonists and anti-inflammatory peptides attract research interest.

Mechanisms of endometriosis pain: - Inflammatory pain: Prostaglandins and cytokines from active lesions directly activate nociceptors in pelvic tissue - Neurogenic inflammation: Endometriosis lesions develop their own nerve supply; these nerves become sensitised and contribute to allodynia (pain from non-painful stimuli) and hyperalgesia - Central sensitisation: Chronic pelvic pain leads to maladaptive changes in spinal cord and brain pain processing, meaning pain persists even when peripheral inflammation is controlled — this explains why surgical removal of lesions does not always resolve pain

Why this matters for peptide research: - GnRH agonists primarily address hormonal/inflammatory drivers but have limited effect on central sensitisation — explaining why pain recurrence is common and why some women have persistent pain even in a hypo-oestrogenic state - BPC-157 and similar peptides with neuromodulatory and anti-inflammatory properties theoretically address different points in the pain cascade

Current evidence-based analgesic approaches in UK practice: - NSAIDs (naproxen, mefenamic acid) as first-line - Combined oral contraceptive pill or continuous progestogen - GnRH agonists with add-back for more severe disease - Adjuvant agents: amitriptyline, pregabalin, duloxetine for central sensitisation component (off-label in NICE guidance) - Specialist pelvic pain physiotherapy and psychological support

For UK women navigating endometriosis, understanding what is accessible through the NHS, and what falls into research territory, is critical for informed decision-making.

NHS access pathways: - GP referral to gynaecology is the standard first step; request referral to a BSGE-accredited endometriosis centre for complex or recurrent disease - GnRH agonists (goserelin, leuprorelin) are available on NHS prescription through gynaecology services - Endometriosis UK (endometriosis-uk.org) maintains a helpline, local support groups, and a comprehensive list of BSGE centres - NICE guideline NG73 sets minimum standards for NHS endometriosis care that your GP and gynaecologist should follow

Private access: - Private gynaecology consultations (£200–£400 initial) with access to the same GnRH agonists, plus potentially faster access to laparoscopy - Some private practitioners have interest in integrative approaches, though no private UK practitioner can legally prescribe BPC-157

Research peptides and endometriosis: - BPC-157 and similar compounds are available from research peptide suppliers in the UK for laboratory use only — they are not regulated for human use and no UK medical professional can supervise their use for endometriosis - Women considering any research peptide for pain management should discuss the full risk profile with their GP or gynaecologist

Key organisations: - Endometriosis UK: national charity, helpline 0808 808 2227 - BSGE (British Society for Gynaecological Endoscopy): accredits specialist centres - NICE NG73: the current evidence-based UK clinical guideline

*This article is for educational purposes only. Endometriosis is a complex medical condition requiring proper clinical assessment and management. Do not self-treat with research peptides. Consult your GP or a BSGE specialist for personalised care.*